Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218406 · ClinicalTrials.gov registry record
Comparison of Merit Prelude Ideal and Terumo Glidesheath Slender Radial Artery Sheaths
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 554
- Enrollment target
NCT07218406: Completed study, sponsored by NYU Langone Health.
NCT07218406 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 554 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07218406 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 554 participants
- Enrollment target
Study Summary
The aim of this study is to determine physician preference of sheath type based on a qualitative survey utilizing an EPIC-based randomization platform.
Primary Outcome
Outcome measure is assessed by the Qualitative survey of physician satisfaction. The survey asks physicians to rate 6 items from 1 being the worst (very bad) to 5 being the best (very good) about the radial artery sheath used in their case. Total scores range from 6-30, with higher scores indicating greater satisfaction with the device.
Interventions
- DEVICE Terumo Glidesheath Slender sheath
- DEVICE Merit Prelude Ideal sheath
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 554 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2026-04-01 |
What the finished NCT07218406 record still lists
NCT07218406 is an observational study that tracks outcomes without assigning an intervention. The registered 554 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Terumo Glidesheath Slender sheath is the first listed.
NCT07218406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07218406 about?
NCT07218406 is a clinical study titled "Comparison of Merit Prelude Ideal and Terumo Glidesheath Slender Radial Artery Sheaths". The aim of this study is to determine physician preference of sheath type based on a qualitative survey utilizing an EPIC-based randomization platform.
What is the current status of trial NCT07218406?
This trial is currently completed. The enrollment target is 554 participants. The study started on 2025-10-20. Estimated completion is 2026-04-01.
What interventions are being tested in trial NCT07218406?
The interventions under investigation include: Terumo Glidesheath Slender sheath (DEVICE), Merit Prelude Ideal sheath (DEVICE).
Who is sponsoring clinical trial NCT07218406?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI